The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Roots Analysis
Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community
153
views

Antibody drugconjugates (ADCs) represent a transformative approach to modern cancertreatment; over the years, this upcoming class of targeted therapeutic agentshas generated significant enthusiasm within the medical science community

 

Roots Analysis is pleased toannounce the publication of its recent study, titled, AntibodyDrug Conjugates Market (5th Edition), 2019-2030.”

 

The report features an extensive study of thecurrent market landscape, offering an informed opinion on the likely adoptionof these therapeutics over the next decade. It features an in-depth analysis,highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:

§ A detailedassessment of the current market landscape of ADCs. 

§ Elaborate profiles ofthe clinical stage companies (shortlisted based on phase of development of thelead drug) and their respective product portfolios.

§ An analysis of themost commonly targeted therapeutic indications and details of ADC candidatesbeing developed against them, highlighting key epidemiological facts about thediseases and currently available treatment options, other than ADCs.

§ A list of key opinionleaders (KOLs) within this domain.

§ An insightfulcompetitiveness analysis of biological targets.

§ An analysis of thepartnerships that have been established in the recent past.

§  An analysis of the investments made.

§  A study of thevarious grants that have been awarded to research institutes engaged inprojects related to ADCs, between 2011 and 2019 (till April).

§  An elaboratediscussion on the various strategies that can be adopted by the drug developersacross key commercialization stages, namely prior to product launch, during /post launch.

§  An analysis of thekey promotional strategies that have been adopted by the developers of marketedproducts.

§  An assessment of thevarious therapeutics that are being evaluated in combination with ADCs.

§  A review of theevolution of ADC conjugation technologies.

§  An overview of thestudies conducted to better analyze non-clinical data and supportfirst-in-human (FIH) dose selection in ADCs.

§  An elaboratediscussion on various factors that form the basis for the pricing of ADCproducts.

§  A case study onmanufacturing of ADCs, highlighting the key challenges, and a list of contractservice providers that are involved in this domain.

§  A case study oncompanies offering companion diagnostics.

§  A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)

§ Type of payload

§ MMAE

§ DM4

§ Camptothecin

§ AM1

§ MMAF

  • Type of linker

§ VC

§ Sulfo-SPDB

§ SMCC

§ VA

§ Hydrazone linker

§ Others

  • Target Indications

§ Breast Cancer

§ Lymphoma

§ Leukemia

§ Urothelial cancer

§ Lung cancer

§ Ovaria cancer

§ Others

  • Target Antigen

§ CD30

§ HER2

§ CD22

§ CD33

§ Others

§ Small Molecule

  • Technology Providers

§ Seattle Genetics

§ ImmunoGen

§ StemCentRx

§ Immunomedics

§ Others

  • Key Geographies

§ North America

§ Europe

§ Asia Pacific

 

Transcripts of interviews heldwith the following senior level representatives of stakeholder companies:

§ Alan Burnett(Professor, School of Medicine, Cardiff University)

§ Aldo Braca (Presidentand Chief Executive Officer) and Giorgio Salciarini (Technical BusinessDevelopment Senior Manager, BSP Pharmaceuticals)

§ Anthony DeBoer(Director, Business Development, Synaffix)

§ Christian Bailly(Director of CDMO, Pierre Fabre)

§ Christian Rohlff,(Chief Executive Officer and Founder, Oxford BioTherapeutics)

§ Denis Angioletti(Chief Commercial Officer, Cerbios-Pharma)

§ John Burt (ChiefExecutive Officer, Abzena)

§ Jennifer L. Mitcham(Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group ProductManager, Catalent Pharma Solutions)

§ Laurent Ducry (Headof Bioconjugates Commercial Development, Lonza)

§ Mark Wright (SiteHead, Piramal Healthcare)

§ Sasha Koniev (ChiefExecutive Officer & Co-Founder, Syndivia)

§ Tatsuya Okuzumi(Associate General Manager, Ajinomoto Bio-Pharma Services)

§ Toshimitsu Uenaka(Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)

§ Wouter Verhoeven(Chief Business Officer, NBE-Therapeutics)

 

Keycompanies covered in the report

§ Bristol Myers Squibb

§ AbbVie

§ Astellas Pharma

§ AstraZeneca

§ Daiichi Sankyo

§ Pfizer

§ Roche / Genentech

§ Synthon

§ Bayer HealthCare

§ BiotestPharmaceuticals

 

Formore information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

Other Offerings

1.     ADC Contract Manufacturing Market (3rdEdition), 2018-2030

2.     Gene Therapy Market (3rd Edition), 2019 - 2030

3.     Global T-Cell (CAR-T, TCR, and TIL) TherapyMarket (4thEdition), 2019 – 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com